FMP
Elevation Oncology, Inc.
ELEV
NASDAQ
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.
0.58 USD
-0.0457 (-7.88%)
About
ceo
Mr. Joseph J. Ferra Jr.
sector
Healthcare
industry
Biotechnology
exchange
NASDAQ
Description
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.
CIK
0001783032
ISIN
US28623U1016
CUSIP
28623U101
Address
888 Seventh Avenue
Phone
716 371 1125
Country
US
Employee
29
IPO Date
Jun 25, 2021
Key Executives
